Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Free Cash Flow (2018 - 2025)

Entera Bio has reported Free Cash Flow over the past 8 years, most recently at -$1.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 26.53% year-over-year to -$1.9 million, compared with a TTM value of -$7.5 million through Dec 2025, down 9.62%, and an annual FY2025 reading of -$7.5 million, down 9.62% over the prior year.
  • Free Cash Flow came in at -$1.9 million for Q4 2025, up from -$2.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.3 million in Q2 2024 to a low of -$4.8 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$2.1 million (2021), compared with a mean of -$2.2 million.
  • The sharpest move saw Free Cash Flow plummeted 107.45% in 2022, then surged 66.36% in 2023.
  • Over 5 years, Free Cash Flow stood at -$2.5 million in 2021, then rose by 20.14% to -$2.0 million in 2022, then crashed by 30.19% to -$2.6 million in 2023, then skyrocketed by 43.94% to -$1.5 million in 2024, then dropped by 26.53% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Free Cash Flow are -$1.9 million (Q4 2025), -$2.5 million (Q3 2025), and -$1.7 million (Q2 2025).